论文部分内容阅读
目的:分析可溶性CD40(sCD40)在尿毒症患者血浆中的水平及其临床意义。方法:选取我院2013年5月至2014年5月间收治的尿毒症患者60例,选取30例尿毒症未透析患者,记为尿毒症组;选取30例血液透析患者,记为血液透析组;另外选取3 0例正常人作为正常组;利用酶联免疫吸附试验对尿毒症组和血液透析组以及正常组分别检测血浆中可溶性CD40(sCD40)的浓度,分析可溶性CD40(sCD40)和SCr以及CRP的相关性,观察血液透析对可溶性CD40(sCD40)的影响。结果:尿毒症组和血液透析组血浆中的可溶性CD40(sCD40)水平明显比对照组高P<0.05,血液透析组可溶性CD40(sCD40)水平和尿毒症组的差异较明显P<0.05,具有统计学意义。尿毒症组可溶性CD40(sCD4 0水平和SCr以及CRP成正相关,而血液透析组的可溶性CD40(sCD)40)和SCr以及CRP的指标无明显关系P>0.05,无统计学意义。经过一次血液透析后,患者透析前和透析后的可溶性CD40(sCD40)水平无明显差异P>0.05。结论:可溶性CD40(sCD40)在尿毒症患者血浆中的水平呈现升高的趋势,血液透析患者尤为明显。
Objective: To analyze the plasma level of soluble CD40 (sCD40) in patients with uremia and its clinical significance. Methods: Sixty uremic patients admitted to our hospital from May 2013 to May 2014 were enrolled in this study. Twenty uremic patients without uremia were enrolled as uremia group. Thirty patients with hemodialysis were enrolled as hemodialysis group ; Another 30 normal individuals were selected as normal group; the concentration of soluble CD40 (sCD40) in plasma was detected by enzyme-linked immunosorbent assay (ELISA) and the levels of soluble CD40 (sCD40) and SCr in uremia group, hemodialysis group and normal group CRP, observe the effect of hemodialysis on soluble CD40 (sCD40). Results: The plasma CD40 (sCD40) levels in uremia group and hemodialysis group were significantly higher than those in control group (P <0.05). The difference between soluble CD40 (sCD40) level and uremia group in hemodialysis group was more significant than that in control group Significance of learning. Uremic group soluble CD40 (sCD40 levels and SCr and CRP positive correlation, and hemodialysis group soluble CD40 (sCD) 40) and SCr and CRP index no significant correlation P> 0.05, no statistical significance. After a hemodialysis, there was no significant difference in the level of soluble CD40 (sCD40) before and after dialysis in patients with P> 0.05. Conclusion: The level of soluble CD40 (sCD40) in plasma of patients with uremia shows an increasing trend, especially in hemodialysis patients.